nodes	percent_of_prediction	percent_of_DWPC	metapath
Mitoxantrone—sarcoma—head and neck cancer	0.567	1	CtDrD
Mitoxantrone—CYP1B1—Docetaxel—head and neck cancer	0.0636	0.234	CbGbCtD
Mitoxantrone—ABCC1—Vinblastine—head and neck cancer	0.0548	0.202	CbGbCtD
Mitoxantrone—ABCC1—Docetaxel—head and neck cancer	0.0452	0.166	CbGbCtD
Mitoxantrone—ABCG2—Fluorouracil—head and neck cancer	0.0396	0.146	CbGbCtD
Mitoxantrone—ABCG2—Docetaxel—head and neck cancer	0.0302	0.111	CbGbCtD
Mitoxantrone—ABCB1—Vinblastine—head and neck cancer	0.0132	0.0486	CbGbCtD
Mitoxantrone—ABCB1—Docetaxel—head and neck cancer	0.0109	0.0401	CbGbCtD
Mitoxantrone—CYP3A4—Vinblastine—head and neck cancer	0.00792	0.0291	CbGbCtD
Mitoxantrone—Nail pigmentation—Hydroxyurea—head and neck cancer	0.00711	0.0763	CcSEcCtD
Mitoxantrone—CYP3A4—Docetaxel—head and neck cancer	0.00653	0.024	CbGbCtD
Mitoxantrone—Ureteric obstruction—Hydroxyurea—head and neck cancer	0.00409	0.0438	CcSEcCtD
Mitoxantrone—Urine output—Hydroxyurea—head and neck cancer	0.00387	0.0415	CcSEcCtD
Mitoxantrone—Onycholysis—Docetaxel—head and neck cancer	0.00257	0.0276	CcSEcCtD
Mitoxantrone—Cardiotoxicity—Fluorouracil—head and neck cancer	0.00205	0.022	CcSEcCtD
Mitoxantrone—Ischaemia—Vinblastine—head and neck cancer	0.00202	0.0216	CcSEcCtD
Mitoxantrone—Myelodysplastic syndrome—Docetaxel—head and neck cancer	0.00174	0.0186	CcSEcCtD
Mitoxantrone—Myelosuppression—Vinblastine—head and neck cancer	0.00157	0.0168	CcSEcCtD
Mitoxantrone—Cardiotoxicity—Docetaxel—head and neck cancer	0.00148	0.0159	CcSEcCtD
Mitoxantrone—Myelosuppression—Hydroxyurea—head and neck cancer	0.00143	0.0153	CcSEcCtD
Mitoxantrone—PIM1—hair follicle—head and neck cancer	0.00139	0.115	CbGeAlD
Mitoxantrone—Mucosal inflammation—Hydroxyurea—head and neck cancer	0.00121	0.013	CcSEcCtD
Mitoxantrone—Platelet count decreased—Hydroxyurea—head and neck cancer	0.00113	0.0121	CcSEcCtD
Mitoxantrone—Febrile neutropenia—Hydroxyurea—head and neck cancer	0.00111	0.012	CcSEcCtD
Mitoxantrone—Myelosuppression—Fluorouracil—head and neck cancer	0.00103	0.011	CcSEcCtD
Mitoxantrone—Enteritis—Docetaxel—head and neck cancer	0.00102	0.0109	CcSEcCtD
Mitoxantrone—Bone marrow depression—Hydroxyurea—head and neck cancer	0.000993	0.0107	CcSEcCtD
Mitoxantrone—Sudden death—Fluorouracil—head and neck cancer	0.000943	0.0101	CcSEcCtD
Mitoxantrone—Cardiomyopathy—Fluorouracil—head and neck cancer	0.000943	0.0101	CcSEcCtD
Mitoxantrone—Local reaction—Fluorouracil—head and neck cancer	0.000872	0.00935	CcSEcCtD
Mitoxantrone—Extravasation—Vinblastine—head and neck cancer	0.000843	0.00904	CcSEcCtD
Mitoxantrone—Febrile neutropenia—Fluorouracil—head and neck cancer	0.000802	0.0086	CcSEcCtD
Mitoxantrone—TOP2A—Vindesine—Vinblastine—head and neck cancer	0.000776	0.317	CbGdCrCtD
Mitoxantrone—BTK—connective tissue—head and neck cancer	0.000774	0.0641	CbGeAlD
Mitoxantrone—Bone pain—Vinblastine—head and neck cancer	0.000768	0.00823	CcSEcCtD
Mitoxantrone—Amenorrhoea—Hydroxyurea—head and neck cancer	0.000763	0.00818	CcSEcCtD
Mitoxantrone—TOP2A—Paclitaxel—Docetaxel—head and neck cancer	0.000761	0.311	CbGdCrCtD
Mitoxantrone—Myelosuppression—Docetaxel—head and neck cancer	0.000743	0.00797	CcSEcCtD
Mitoxantrone—Hyperuricaemia—Hydroxyurea—head and neck cancer	0.000723	0.00775	CcSEcCtD
Mitoxantrone—Interstitial pneumonia—Docetaxel—head and neck cancer	0.000721	0.00773	CcSEcCtD
Mitoxantrone—Ulcer—Hydroxyurea—head and neck cancer	0.000709	0.0076	CcSEcCtD
Mitoxantrone—Hepatic enzyme increased—Hydroxyurea—head and neck cancer	0.000709	0.0076	CcSEcCtD
Mitoxantrone—Blood uric acid increased—Hydroxyurea—head and neck cancer	0.000683	0.00732	CcSEcCtD
Mitoxantrone—PIM1—connective tissue—head and neck cancer	0.00067	0.0555	CbGeAlD
Mitoxantrone—Blood urea increased—Hydroxyurea—head and neck cancer	0.000633	0.00679	CcSEcCtD
Mitoxantrone—Mucosal inflammation—Docetaxel—head and neck cancer	0.000629	0.00675	CcSEcCtD
Mitoxantrone—Phlebitis—Vinblastine—head and neck cancer	0.00062	0.00664	CcSEcCtD
Mitoxantrone—Necrosis—Fluorouracil—head and neck cancer	0.000615	0.00659	CcSEcCtD
Mitoxantrone—SLC47A2—head—head and neck cancer	0.000605	0.0501	CbGeAlD
Mitoxantrone—Myocardial ischaemia—Fluorouracil—head and neck cancer	0.0006	0.00644	CcSEcCtD
Mitoxantrone—Febrile neutropenia—Docetaxel—head and neck cancer	0.000579	0.00621	CcSEcCtD
Mitoxantrone—BTK—lymphoid tissue—head and neck cancer	0.000566	0.0468	CbGeAlD
Mitoxantrone—PIM1—trachea—head and neck cancer	0.000563	0.0466	CbGeAlD
Mitoxantrone—Extravasation—Fluorouracil—head and neck cancer	0.000553	0.00593	CcSEcCtD
Mitoxantrone—CYP1B1—hair follicle—head and neck cancer	0.000547	0.0453	CbGeAlD
Mitoxantrone—Renal failure acute—Hydroxyurea—head and neck cancer	0.000527	0.00565	CcSEcCtD
Mitoxantrone—BTK—thyroid gland—head and neck cancer	0.000514	0.0425	CbGeAlD
Mitoxantrone—Ulcer—Fluorouracil—head and neck cancer	0.00051	0.00547	CcSEcCtD
Mitoxantrone—Haemoglobin decreased—Docetaxel—head and neck cancer	0.000506	0.00543	CcSEcCtD
Mitoxantrone—ABCC1—hair follicle—head and neck cancer	0.000492	0.0408	CbGeAlD
Mitoxantrone—Interstitial lung disease—Docetaxel—head and neck cancer	0.000492	0.00528	CcSEcCtD
Mitoxantrone—PIM1—lymphoid tissue—head and neck cancer	0.00049	0.0406	CbGeAlD
Mitoxantrone—TOP2A—Vinorelbine—Vinblastine—head and neck cancer	0.000489	0.2	CbGdCrCtD
Mitoxantrone—Blood creatinine increased—Hydroxyurea—head and neck cancer	0.000456	0.00489	CcSEcCtD
Mitoxantrone—PIM1—thyroid gland—head and neck cancer	0.000445	0.0369	CbGeAlD
Mitoxantrone—Necrosis—Docetaxel—head and neck cancer	0.000444	0.00476	CcSEcCtD
Mitoxantrone—Pancytopenia—Vinblastine—head and neck cancer	0.000438	0.0047	CcSEcCtD
Mitoxantrone—Myocardial ischaemia—Docetaxel—head and neck cancer	0.000433	0.00465	CcSEcCtD
Mitoxantrone—Sepsis—Fluorouracil—head and neck cancer	0.000419	0.00449	CcSEcCtD
Mitoxantrone—TOP2A—Vincristine—Vinblastine—head and neck cancer	0.000418	0.171	CbGdCrCtD
Mitoxantrone—Acute coronary syndrome—Vinblastine—head and neck cancer	0.000405	0.00435	CcSEcCtD
Mitoxantrone—Myocardial infarction—Vinblastine—head and neck cancer	0.000403	0.00432	CcSEcCtD
Mitoxantrone—Pancytopenia—Hydroxyurea—head and neck cancer	0.0004	0.00428	CcSEcCtD
Mitoxantrone—Extravasation—Docetaxel—head and neck cancer	0.000399	0.00428	CcSEcCtD
Mitoxantrone—Swelling—Fluorouracil—head and neck cancer	0.000397	0.00426	CcSEcCtD
Mitoxantrone—Amenorrhoea—Docetaxel—head and neck cancer	0.000396	0.00425	CcSEcCtD
Mitoxantrone—PIM1—head—head and neck cancer	0.000395	0.0327	CbGeAlD
Mitoxantrone—Neutropenia—Hydroxyurea—head and neck cancer	0.000393	0.00422	CcSEcCtD
Mitoxantrone—Agranulocytosis—Vinblastine—head and neck cancer	0.000384	0.00412	CcSEcCtD
Mitoxantrone—Weight increased—Hydroxyurea—head and neck cancer	0.000383	0.00411	CcSEcCtD
Mitoxantrone—Drowsiness—Hydroxyurea—head and neck cancer	0.000375	0.00402	CcSEcCtD
Mitoxantrone—Haemoglobin—Vinblastine—head and neck cancer	0.000371	0.00398	CcSEcCtD
Mitoxantrone—Haemorrhage—Vinblastine—head and neck cancer	0.000369	0.00396	CcSEcCtD
Mitoxantrone—Blood bilirubin increased—Docetaxel—head and neck cancer	0.000368	0.00395	CcSEcCtD
Mitoxantrone—Pharyngitis—Vinblastine—head and neck cancer	0.000366	0.00393	CcSEcCtD
Mitoxantrone—Stomatitis—Hydroxyurea—head and neck cancer	0.000366	0.00392	CcSEcCtD
Mitoxantrone—Bone pain—Docetaxel—head and neck cancer	0.000364	0.0039	CcSEcCtD
Mitoxantrone—Cardiac failure—Fluorouracil—head and neck cancer	0.000359	0.00385	CcSEcCtD
Mitoxantrone—Gastrointestinal haemorrhage—Fluorouracil—head and neck cancer	0.00035	0.00376	CcSEcCtD
Mitoxantrone—Haemoglobin—Hydroxyurea—head and neck cancer	0.000338	0.00363	CcSEcCtD
Mitoxantrone—Haemorrhage—Hydroxyurea—head and neck cancer	0.000337	0.00361	CcSEcCtD
Mitoxantrone—Alopecia—Vinblastine—head and neck cancer	0.000326	0.0035	CcSEcCtD
Mitoxantrone—BTK—lymph node—head and neck cancer	0.000319	0.0264	CbGeAlD
Mitoxantrone—Sepsis—Docetaxel—head and neck cancer	0.000302	0.00324	CcSEcCtD
Mitoxantrone—Chills—Hydroxyurea—head and neck cancer	0.000302	0.00324	CcSEcCtD
Mitoxantrone—Ill-defined disorder—Vinblastine—head and neck cancer	0.000298	0.0032	CcSEcCtD
Mitoxantrone—Alopecia—Hydroxyurea—head and neck cancer	0.000298	0.00319	CcSEcCtD
Mitoxantrone—Anaemia—Vinblastine—head and neck cancer	0.000297	0.00319	CcSEcCtD
Mitoxantrone—Phlebitis—Docetaxel—head and neck cancer	0.000294	0.00315	CcSEcCtD
Mitoxantrone—Erythema—Hydroxyurea—head and neck cancer	0.000293	0.00314	CcSEcCtD
Mitoxantrone—Malaise—Vinblastine—head and neck cancer	0.00029	0.00311	CcSEcCtD
Mitoxantrone—Leukopenia—Vinblastine—head and neck cancer	0.000288	0.00309	CcSEcCtD
Mitoxantrone—Pancytopenia—Fluorouracil—head and neck cancer	0.000288	0.00308	CcSEcCtD
Mitoxantrone—Swelling—Docetaxel—head and neck cancer	0.000287	0.00307	CcSEcCtD
Mitoxantrone—Upper respiratory tract infection—Fluorouracil—head and neck cancer	0.000281	0.00302	CcSEcCtD
Mitoxantrone—Cardiac failure congestive—Docetaxel—head and neck cancer	0.000279	0.00299	CcSEcCtD
Mitoxantrone—Convulsion—Vinblastine—head and neck cancer	0.000279	0.00299	CcSEcCtD
Mitoxantrone—Hypertension—Vinblastine—head and neck cancer	0.000278	0.00298	CcSEcCtD
Mitoxantrone—PIM1—lymph node—head and neck cancer	0.000277	0.0229	CbGeAlD
Mitoxantrone—Ill-defined disorder—Hydroxyurea—head and neck cancer	0.000272	0.00292	CcSEcCtD
Mitoxantrone—Pneumonia—Fluorouracil—head and neck cancer	0.000272	0.00291	CcSEcCtD
Mitoxantrone—Anaemia—Hydroxyurea—head and neck cancer	0.000271	0.00291	CcSEcCtD
Mitoxantrone—Discomfort—Vinblastine—head and neck cancer	0.00027	0.0029	CcSEcCtD
Mitoxantrone—ABCC1—parotid gland—head and neck cancer	0.000269	0.0223	CbGeAlD
Mitoxantrone—Acute coronary syndrome—Fluorouracil—head and neck cancer	0.000266	0.00285	CcSEcCtD
Mitoxantrone—Myocardial infarction—Fluorouracil—head and neck cancer	0.000265	0.00284	CcSEcCtD
Mitoxantrone—Malaise—Hydroxyurea—head and neck cancer	0.000264	0.00283	CcSEcCtD
Mitoxantrone—CYP1B1—connective tissue—head and neck cancer	0.000263	0.0218	CbGeAlD
Mitoxantrone—Stomatitis—Fluorouracil—head and neck cancer	0.000263	0.00282	CcSEcCtD
Mitoxantrone—Conjunctivitis—Fluorouracil—head and neck cancer	0.000262	0.00281	CcSEcCtD
Mitoxantrone—Urinary tract infection—Fluorouracil—head and neck cancer	0.000262	0.00281	CcSEcCtD
Mitoxantrone—Leukopenia—Hydroxyurea—head and neck cancer	0.000262	0.00281	CcSEcCtD
Mitoxantrone—TOP2A—thyroid gland—head and neck cancer	0.000261	0.0216	CbGeAlD
Mitoxantrone—Cardiac failure—Docetaxel—head and neck cancer	0.000259	0.00278	CcSEcCtD
Mitoxantrone—Thrombocytopenia—Vinblastine—head and neck cancer	0.000257	0.00275	CcSEcCtD
Mitoxantrone—Convulsion—Hydroxyurea—head and neck cancer	0.000254	0.00272	CcSEcCtD
Mitoxantrone—Hyponatraemia—Docetaxel—head and neck cancer	0.000254	0.00272	CcSEcCtD
Mitoxantrone—Sinusitis—Fluorouracil—head and neck cancer	0.000253	0.00272	CcSEcCtD
Mitoxantrone—Gastrointestinal haemorrhage—Docetaxel—head and neck cancer	0.000253	0.00271	CcSEcCtD
Mitoxantrone—Agranulocytosis—Fluorouracil—head and neck cancer	0.000252	0.0027	CcSEcCtD
Mitoxantrone—Anorexia—Vinblastine—head and neck cancer	0.00025	0.00268	CcSEcCtD
Mitoxantrone—Discomfort—Hydroxyurea—head and neck cancer	0.000247	0.00264	CcSEcCtD
Mitoxantrone—Haemoglobin—Fluorouracil—head and neck cancer	0.000244	0.00261	CcSEcCtD
Mitoxantrone—Rhinitis—Fluorouracil—head and neck cancer	0.000243	0.00261	CcSEcCtD
Mitoxantrone—Haemorrhage—Fluorouracil—head and neck cancer	0.000242	0.0026	CcSEcCtD
Mitoxantrone—Pharyngitis—Fluorouracil—head and neck cancer	0.000241	0.00258	CcSEcCtD
Mitoxantrone—Oedema—Hydroxyurea—head and neck cancer	0.000239	0.00257	CcSEcCtD
Mitoxantrone—SLC47A1—thyroid gland—head and neck cancer	0.000239	0.0197	CbGeAlD
Mitoxantrone—Infection—Hydroxyurea—head and neck cancer	0.000238	0.00255	CcSEcCtD
Mitoxantrone—Paraesthesia—Vinblastine—head and neck cancer	0.000236	0.00253	CcSEcCtD
Mitoxantrone—Dehydration—Docetaxel—head and neck cancer	0.000235	0.00252	CcSEcCtD
Mitoxantrone—Thrombocytopenia—Hydroxyurea—head and neck cancer	0.000234	0.00251	CcSEcCtD
Mitoxantrone—Skin disorder—Hydroxyurea—head and neck cancer	0.000232	0.00249	CcSEcCtD
Mitoxantrone—Abdominal pain upper—Docetaxel—head and neck cancer	0.000231	0.00248	CcSEcCtD
Mitoxantrone—Anorexia—Hydroxyurea—head and neck cancer	0.000228	0.00245	CcSEcCtD
Mitoxantrone—Decreased appetite—Vinblastine—head and neck cancer	0.000228	0.00245	CcSEcCtD
Mitoxantrone—Aspartate aminotransferase increased—Docetaxel—head and neck cancer	0.000228	0.00244	CcSEcCtD
Mitoxantrone—Constipation—Vinblastine—head and neck cancer	0.000224	0.00241	CcSEcCtD
Mitoxantrone—Pain—Vinblastine—head and neck cancer	0.000224	0.00241	CcSEcCtD
Mitoxantrone—Alanine aminotransferase increased—Docetaxel—head and neck cancer	0.000223	0.00239	CcSEcCtD
Mitoxantrone—ABCG2—parotid gland—head and neck cancer	0.000223	0.0184	CbGeAlD
Mitoxantrone—Arrhythmia—Fluorouracil—head and neck cancer	0.000217	0.00232	CcSEcCtD
Mitoxantrone—Feeling abnormal—Vinblastine—head and neck cancer	0.000216	0.00232	CcSEcCtD
Mitoxantrone—Gastrointestinal pain—Vinblastine—head and neck cancer	0.000215	0.0023	CcSEcCtD
Mitoxantrone—Alopecia—Fluorouracil—head and neck cancer	0.000214	0.0023	CcSEcCtD
Mitoxantrone—ABCG2—saliva-secreting gland—head and neck cancer	0.000213	0.0177	CbGeAlD
Mitoxantrone—Dyspnoea—Hydroxyurea—head and neck cancer	0.000213	0.00229	CcSEcCtD
Mitoxantrone—Somnolence—Hydroxyurea—head and neck cancer	0.000213	0.00228	CcSEcCtD
Mitoxantrone—SLC47A1—head—head and neck cancer	0.000212	0.0175	CbGeAlD
Mitoxantrone—Erythema—Fluorouracil—head and neck cancer	0.000211	0.00226	CcSEcCtD
Mitoxantrone—Dyspepsia—Hydroxyurea—head and neck cancer	0.000211	0.00226	CcSEcCtD
Mitoxantrone—Decreased appetite—Hydroxyurea—head and neck cancer	0.000208	0.00223	CcSEcCtD
Mitoxantrone—Pancytopenia—Docetaxel—head and neck cancer	0.000208	0.00223	CcSEcCtD
Mitoxantrone—Abdominal pain—Vinblastine—head and neck cancer	0.000207	0.00222	CcSEcCtD
Mitoxantrone—Fatigue—Hydroxyurea—head and neck cancer	0.000206	0.00221	CcSEcCtD
Mitoxantrone—Constipation—Hydroxyurea—head and neck cancer	0.000205	0.00219	CcSEcCtD
Mitoxantrone—Pain—Hydroxyurea—head and neck cancer	0.000205	0.00219	CcSEcCtD
Mitoxantrone—Neutropenia—Docetaxel—head and neck cancer	0.000204	0.00219	CcSEcCtD
Mitoxantrone—Weight increased—Docetaxel—head and neck cancer	0.000199	0.00213	CcSEcCtD
Mitoxantrone—Vision blurred—Fluorouracil—head and neck cancer	0.000199	0.00213	CcSEcCtD
Mitoxantrone—ABCC1—trachea—head and neck cancer	0.000199	0.0165	CbGeAlD
Mitoxantrone—Weight decreased—Docetaxel—head and neck cancer	0.000198	0.00212	CcSEcCtD
Mitoxantrone—Feeling abnormal—Hydroxyurea—head and neck cancer	0.000197	0.00211	CcSEcCtD
Mitoxantrone—Pneumonia—Docetaxel—head and neck cancer	0.000196	0.0021	CcSEcCtD
Mitoxantrone—Anaemia—Fluorouracil—head and neck cancer	0.000195	0.00209	CcSEcCtD
Mitoxantrone—Hypersensitivity—Vinblastine—head and neck cancer	0.000193	0.00207	CcSEcCtD
Mitoxantrone—CYP1B1—lymphoid tissue—head and neck cancer	0.000192	0.0159	CbGeAlD
Mitoxantrone—Acute coronary syndrome—Docetaxel—head and neck cancer	0.000192	0.00206	CcSEcCtD
Mitoxantrone—Renal failure—Docetaxel—head and neck cancer	0.000192	0.00205	CcSEcCtD
Mitoxantrone—Myocardial infarction—Docetaxel—head and neck cancer	0.000191	0.00205	CcSEcCtD
Mitoxantrone—Jaundice—Docetaxel—head and neck cancer	0.00019	0.00204	CcSEcCtD
Mitoxantrone—Stomatitis—Docetaxel—head and neck cancer	0.00019	0.00204	CcSEcCtD
Mitoxantrone—Conjunctivitis—Docetaxel—head and neck cancer	0.000189	0.00203	CcSEcCtD
Mitoxantrone—Body temperature increased—Hydroxyurea—head and neck cancer	0.000189	0.00203	CcSEcCtD
Mitoxantrone—Leukopenia—Fluorouracil—head and neck cancer	0.000189	0.00203	CcSEcCtD
Mitoxantrone—Asthenia—Vinblastine—head and neck cancer	0.000188	0.00202	CcSEcCtD
Mitoxantrone—Convulsion—Fluorouracil—head and neck cancer	0.000183	0.00196	CcSEcCtD
Mitoxantrone—Agranulocytosis—Docetaxel—head and neck cancer	0.000182	0.00195	CcSEcCtD
Mitoxantrone—Myalgia—Fluorouracil—head and neck cancer	0.00018	0.00193	CcSEcCtD
Mitoxantrone—Chest pain—Fluorouracil—head and neck cancer	0.00018	0.00193	CcSEcCtD
Mitoxantrone—Diarrhoea—Vinblastine—head and neck cancer	0.000179	0.00192	CcSEcCtD
Mitoxantrone—Discomfort—Fluorouracil—head and neck cancer	0.000177	0.0019	CcSEcCtD
Mitoxantrone—Hypersensitivity—Hydroxyurea—head and neck cancer	0.000176	0.00189	CcSEcCtD
Mitoxantrone—Haemoglobin—Docetaxel—head and neck cancer	0.000176	0.00189	CcSEcCtD
Mitoxantrone—Rhinitis—Docetaxel—head and neck cancer	0.000175	0.00188	CcSEcCtD
Mitoxantrone—Hepatitis—Docetaxel—head and neck cancer	0.000175	0.00188	CcSEcCtD
Mitoxantrone—Haemorrhage—Docetaxel—head and neck cancer	0.000175	0.00188	CcSEcCtD
Mitoxantrone—CYP1B1—thyroid gland—head and neck cancer	0.000175	0.0145	CbGeAlD
Mitoxantrone—Confusional state—Fluorouracil—head and neck cancer	0.000174	0.00186	CcSEcCtD
Mitoxantrone—Pharyngitis—Docetaxel—head and neck cancer	0.000174	0.00186	CcSEcCtD
Mitoxantrone—Oedema—Fluorouracil—head and neck cancer	0.000172	0.00185	CcSEcCtD
Mitoxantrone—Anaphylactic shock—Fluorouracil—head and neck cancer	0.000172	0.00185	CcSEcCtD
Mitoxantrone—Asthenia—Hydroxyurea—head and neck cancer	0.000172	0.00184	CcSEcCtD
Mitoxantrone—Infection—Fluorouracil—head and neck cancer	0.000171	0.00183	CcSEcCtD
Mitoxantrone—Thrombocytopenia—Fluorouracil—head and neck cancer	0.000169	0.00181	CcSEcCtD
Mitoxantrone—Tachycardia—Fluorouracil—head and neck cancer	0.000168	0.0018	CcSEcCtD
Mitoxantrone—Vomiting—Vinblastine—head and neck cancer	0.000167	0.00179	CcSEcCtD
Mitoxantrone—Headache—Vinblastine—head and neck cancer	0.000164	0.00176	CcSEcCtD
Mitoxantrone—Anorexia—Fluorouracil—head and neck cancer	0.000164	0.00176	CcSEcCtD
Mitoxantrone—Diarrhoea—Hydroxyurea—head and neck cancer	0.000164	0.00176	CcSEcCtD
Mitoxantrone—TOP2A—lymph node—head and neck cancer	0.000162	0.0134	CbGeAlD
Mitoxantrone—Hypotension—Fluorouracil—head and neck cancer	0.000161	0.00173	CcSEcCtD
Mitoxantrone—ABCC1—thyroid gland—head and neck cancer	0.000157	0.013	CbGeAlD
Mitoxantrone—Chills—Docetaxel—head and neck cancer	0.000157	0.00168	CcSEcCtD
Mitoxantrone—Musculoskeletal discomfort—Fluorouracil—head and neck cancer	0.000157	0.00168	CcSEcCtD
Mitoxantrone—Arrhythmia—Docetaxel—head and neck cancer	0.000156	0.00168	CcSEcCtD
Mitoxantrone—Nausea—Vinblastine—head and neck cancer	0.000156	0.00167	CcSEcCtD
Mitoxantrone—CYP1B1—head—head and neck cancer	0.000155	0.0128	CbGeAlD
Mitoxantrone—Paraesthesia—Fluorouracil—head and neck cancer	0.000155	0.00166	CcSEcCtD
Mitoxantrone—Alopecia—Docetaxel—head and neck cancer	0.000155	0.00166	CcSEcCtD
Mitoxantrone—Dyspnoea—Fluorouracil—head and neck cancer	0.000154	0.00165	CcSEcCtD
Mitoxantrone—Somnolence—Fluorouracil—head and neck cancer	0.000153	0.00164	CcSEcCtD
Mitoxantrone—Erythema—Docetaxel—head and neck cancer	0.000152	0.00163	CcSEcCtD
Mitoxantrone—Vomiting—Hydroxyurea—head and neck cancer	0.000152	0.00163	CcSEcCtD
Mitoxantrone—Dyspepsia—Fluorouracil—head and neck cancer	0.000152	0.00163	CcSEcCtD
Mitoxantrone—Rash—Hydroxyurea—head and neck cancer	0.000151	0.00162	CcSEcCtD
Mitoxantrone—Dermatitis—Hydroxyurea—head and neck cancer	0.000151	0.00162	CcSEcCtD
Mitoxantrone—Headache—Hydroxyurea—head and neck cancer	0.00015	0.00161	CcSEcCtD
Mitoxantrone—Decreased appetite—Fluorouracil—head and neck cancer	0.00015	0.00161	CcSEcCtD
Mitoxantrone—Dysgeusia—Docetaxel—head and neck cancer	0.000149	0.0016	CcSEcCtD
Mitoxantrone—SLC47A1—lymph node—head and neck cancer	0.000148	0.0123	CbGeAlD
Mitoxantrone—Back pain—Docetaxel—head and neck cancer	0.000147	0.00158	CcSEcCtD
Mitoxantrone—Pain—Fluorouracil—head and neck cancer	0.000147	0.00158	CcSEcCtD
Mitoxantrone—Nausea—Hydroxyurea—head and neck cancer	0.000142	0.00152	CcSEcCtD
Mitoxantrone—Feeling abnormal—Fluorouracil—head and neck cancer	0.000142	0.00152	CcSEcCtD
Mitoxantrone—Anaemia—Docetaxel—head and neck cancer	0.000141	0.00151	CcSEcCtD
Mitoxantrone—Urticaria—Fluorouracil—head and neck cancer	0.000137	0.00147	CcSEcCtD
Mitoxantrone—Leukopenia—Docetaxel—head and neck cancer	0.000136	0.00146	CcSEcCtD
Mitoxantrone—Body temperature increased—Fluorouracil—head and neck cancer	0.000136	0.00146	CcSEcCtD
Mitoxantrone—Cough—Docetaxel—head and neck cancer	0.000133	0.00143	CcSEcCtD
Mitoxantrone—Convulsion—Docetaxel—head and neck cancer	0.000132	0.00141	CcSEcCtD
Mitoxantrone—Hypertension—Docetaxel—head and neck cancer	0.000131	0.00141	CcSEcCtD
Mitoxantrone—ABCG2—thyroid gland—head and neck cancer	0.00013	0.0108	CbGeAlD
Mitoxantrone—Chest pain—Docetaxel—head and neck cancer	0.00013	0.00139	CcSEcCtD
Mitoxantrone—Myalgia—Docetaxel—head and neck cancer	0.00013	0.00139	CcSEcCtD
Mitoxantrone—Arthralgia—Docetaxel—head and neck cancer	0.00013	0.00139	CcSEcCtD
Mitoxantrone—Hypersensitivity—Fluorouracil—head and neck cancer	0.000127	0.00136	CcSEcCtD
Mitoxantrone—Confusional state—Docetaxel—head and neck cancer	0.000125	0.00134	CcSEcCtD
Mitoxantrone—Oedema—Docetaxel—head and neck cancer	0.000124	0.00133	CcSEcCtD
Mitoxantrone—Anaphylactic shock—Docetaxel—head and neck cancer	0.000124	0.00133	CcSEcCtD
Mitoxantrone—CYP2E1—lymphoid tissue—head and neck cancer	0.000124	0.0103	CbGeAlD
Mitoxantrone—Infection—Docetaxel—head and neck cancer	0.000123	0.00132	CcSEcCtD
Mitoxantrone—Shock—Docetaxel—head and neck cancer	0.000122	0.00131	CcSEcCtD
Mitoxantrone—Thrombocytopenia—Docetaxel—head and neck cancer	0.000122	0.0013	CcSEcCtD
Mitoxantrone—Tachycardia—Docetaxel—head and neck cancer	0.000121	0.0013	CcSEcCtD
Mitoxantrone—Skin disorder—Docetaxel—head and neck cancer	0.000121	0.00129	CcSEcCtD
Mitoxantrone—CYP2E1—Cytochrome P450 - arranged by substrate type—CYP1A1—head and neck cancer	0.00012	0.00225	CbGpPWpGaD
Mitoxantrone—CYP2E1—Oxidation by Cytochrome P450—CYP1A1—head and neck cancer	0.000119	0.00222	CbGpPWpGaD
Mitoxantrone—Anorexia—Docetaxel—head and neck cancer	0.000118	0.00127	CcSEcCtD
Mitoxantrone—Diarrhoea—Fluorouracil—head and neck cancer	0.000118	0.00126	CcSEcCtD
Mitoxantrone—TOP2A—Cell Cycle, Mitotic—CCNA1—head and neck cancer	0.000117	0.00218	CbGpPWpGaD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—TYMS—head and neck cancer	0.000116	0.00217	CbGpPWpGaD
Mitoxantrone—Hypotension—Docetaxel—head and neck cancer	0.000116	0.00125	CcSEcCtD
Mitoxantrone—BTK—BCR signaling pathway—AKT1—head and neck cancer	0.000116	0.00216	CbGpPWpGaD
Mitoxantrone—Musculoskeletal discomfort—Docetaxel—head and neck cancer	0.000113	0.00121	CcSEcCtD
Mitoxantrone—BTK—Activated TLR4 signalling—MAPK3—head and neck cancer	0.000113	0.00211	CbGpPWpGaD
Mitoxantrone—CYP2E1—thyroid gland—head and neck cancer	0.000113	0.00933	CbGeAlD
Mitoxantrone—Paraesthesia—Docetaxel—head and neck cancer	0.000112	0.0012	CcSEcCtD
Mitoxantrone—TOP2A—Circadian rythm related genes—TYMS—head and neck cancer	0.000112	0.00209	CbGpPWpGaD
Mitoxantrone—Dyspnoea—Docetaxel—head and neck cancer	0.000111	0.00119	CcSEcCtD
Mitoxantrone—CYP2E1—Biological oxidations—NAT2—head and neck cancer	0.000111	0.00207	CbGpPWpGaD
Mitoxantrone—Somnolence—Docetaxel—head and neck cancer	0.00011	0.00118	CcSEcCtD
Mitoxantrone—TOP2A—Retinoblastoma (RB) in Cancer—CCND1—head and neck cancer	0.00011	0.00205	CbGpPWpGaD
Mitoxantrone—Vomiting—Fluorouracil—head and neck cancer	0.000109	0.00117	CcSEcCtD
Mitoxantrone—Dyspepsia—Docetaxel—head and neck cancer	0.000109	0.00117	CcSEcCtD
Mitoxantrone—CYP2E1—Metapathway biotransformation—NAT2—head and neck cancer	0.000109	0.00204	CbGpPWpGaD
Mitoxantrone—CYP1B1—lymph node—head and neck cancer	0.000109	0.00899	CbGeAlD
Mitoxantrone—Rash—Fluorouracil—head and neck cancer	0.000109	0.00116	CcSEcCtD
Mitoxantrone—Dermatitis—Fluorouracil—head and neck cancer	0.000108	0.00116	CcSEcCtD
Mitoxantrone—Decreased appetite—Docetaxel—head and neck cancer	0.000108	0.00116	CcSEcCtD
Mitoxantrone—Headache—Fluorouracil—head and neck cancer	0.000108	0.00116	CcSEcCtD
Mitoxantrone—BTK—Activated TLR4 signalling—MAPK1—head and neck cancer	0.000107	0.00201	CbGpPWpGaD
Mitoxantrone—Fatigue—Docetaxel—head and neck cancer	0.000107	0.00115	CcSEcCtD
Mitoxantrone—CYP1B1—Aryl Hydrocarbon Receptor—VEGFA—head and neck cancer	0.000107	0.00199	CbGpPWpGaD
Mitoxantrone—Pain—Docetaxel—head and neck cancer	0.000106	0.00114	CcSEcCtD
Mitoxantrone—Constipation—Docetaxel—head and neck cancer	0.000106	0.00114	CcSEcCtD
Mitoxantrone—BTK—Toll Like Receptor 4 (TLR4) Cascade—MAPK3—head and neck cancer	0.000106	0.00199	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle—CCNA1—head and neck cancer	0.000104	0.00195	CbGpPWpGaD
Mitoxantrone—Feeling abnormal—Docetaxel—head and neck cancer	0.000102	0.0011	CcSEcCtD
Mitoxantrone—Nausea—Fluorouracil—head and neck cancer	0.000102	0.0011	CcSEcCtD
Mitoxantrone—Gastrointestinal pain—Docetaxel—head and neck cancer	0.000102	0.00109	CcSEcCtD
Mitoxantrone—BTK—Toll Like Receptor 4 (TLR4) Cascade—MAPK1—head and neck cancer	0.000101	0.00189	CbGpPWpGaD
Mitoxantrone—CYP2E1—head—head and neck cancer	0.0001	0.00828	CbGeAlD
Mitoxantrone—Abdominal pain—Docetaxel—head and neck cancer	9.83e-05	0.00105	CcSEcCtD
Mitoxantrone—Body temperature increased—Docetaxel—head and neck cancer	9.83e-05	0.00105	CcSEcCtD
Mitoxantrone—BTK—DAP12 signaling—PTEN—head and neck cancer	9.81e-05	0.00183	CbGpPWpGaD
Mitoxantrone—ABCC1—lymph node—head and neck cancer	9.77e-05	0.00809	CbGeAlD
Mitoxantrone—BTK—B Cell Receptor Signaling Pathway—HRAS—head and neck cancer	9.75e-05	0.00182	CbGpPWpGaD
Mitoxantrone—CYP2E1—Phase 1 - Functionalization of compounds—CYP1A1—head and neck cancer	9.75e-05	0.00182	CbGpPWpGaD
Mitoxantrone—CYP1B1—Aryl Hydrocarbon Receptor—MAPK1—head and neck cancer	9.6e-05	0.00179	CbGpPWpGaD
Mitoxantrone—CYP1B1—Aryl Hydrocarbon Receptor Pathway—EGFR—head and neck cancer	9.6e-05	0.00179	CbGpPWpGaD
Mitoxantrone—CYP1B1—Aryl Hydrocarbon Receptor—EGFR—head and neck cancer	9.6e-05	0.00179	CbGpPWpGaD
Mitoxantrone—BTK—Regulation of toll-like receptor signaling pathway—MAPK3—head and neck cancer	9.57e-05	0.00179	CbGpPWpGaD
Mitoxantrone—ABCG2—Fluoropyrimidine Activity—TP53—head and neck cancer	9.56e-05	0.00179	CbGpPWpGaD
Mitoxantrone—BTK—Toll-Like Receptors Cascades—MAPK3—head and neck cancer	9.46e-05	0.00177	CbGpPWpGaD
Mitoxantrone—BTK—Fc epsilon receptor (FCERI) signaling—PTEN—head and neck cancer	9.23e-05	0.00173	CbGpPWpGaD
Mitoxantrone—BTK—DAP12 interactions—PTEN—head and neck cancer	9.23e-05	0.00173	CbGpPWpGaD
Mitoxantrone—ABCB1—epithelium—head and neck cancer	9.18e-05	0.0076	CbGeAlD
Mitoxantrone—Hypersensitivity—Docetaxel—head and neck cancer	9.16e-05	0.000982	CcSEcCtD
Mitoxantrone—BTK—Regulation of toll-like receptor signaling pathway—MAPK1—head and neck cancer	9.11e-05	0.0017	CbGpPWpGaD
Mitoxantrone—BTK—Toll-Like Receptors Cascades—MAPK1—head and neck cancer	9e-05	0.00168	CbGpPWpGaD
Mitoxantrone—Asthenia—Docetaxel—head and neck cancer	8.92e-05	0.000956	CcSEcCtD
Mitoxantrone—BTK—B Cell Receptor Signaling Pathway—AKT1—head and neck cancer	8.61e-05	0.00161	CbGpPWpGaD
Mitoxantrone—BTK—B Cell Activation—PTEN—head and neck cancer	8.54e-05	0.0016	CbGpPWpGaD
Mitoxantrone—Diarrhoea—Docetaxel—head and neck cancer	8.5e-05	0.000912	CcSEcCtD
Mitoxantrone—ABCC1—Defective AMN causes hereditary megaloblastic anemia 1—PTGS2—head and neck cancer	8.41e-05	0.00157	CbGpPWpGaD
Mitoxantrone—BTK—DAP12 signaling—MAPK3—head and neck cancer	8.38e-05	0.00157	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle—RAD51—head and neck cancer	8.38e-05	0.00157	CbGpPWpGaD
Mitoxantrone—CYP1B1—Biological oxidations—GSTM1—head and neck cancer	8.36e-05	0.00156	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metapathway biotransformation—GSTM1—head and neck cancer	8.25e-05	0.00154	CbGpPWpGaD
Mitoxantrone—ABCB1—trachea—head and neck cancer	8.12e-05	0.00672	CbGeAlD
Mitoxantrone—BTK—Immune System—STAT6—head and neck cancer	8.09e-05	0.00151	CbGpPWpGaD
Mitoxantrone—ABCG2—lymph node—head and neck cancer	8.09e-05	0.0067	CbGeAlD
Mitoxantrone—ABCC1—Transmembrane transport of small molecules—ATP7B—head and neck cancer	8.09e-05	0.00151	CbGpPWpGaD
Mitoxantrone—BTK—DAP12 signaling—MAPK1—head and neck cancer	7.98e-05	0.00149	CbGpPWpGaD
Mitoxantrone—BTK—DAP12 signaling—EGFR—head and neck cancer	7.98e-05	0.00149	CbGpPWpGaD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—CASP8—head and neck cancer	7.94e-05	0.00149	CbGpPWpGaD
Mitoxantrone—CYP1B1—Biological oxidations—CYP1A1—head and neck cancer	7.93e-05	0.00148	CbGpPWpGaD
Mitoxantrone—Vomiting—Docetaxel—head and neck cancer	7.9e-05	0.000847	CcSEcCtD
Mitoxantrone—BTK—Regulation of toll-like receptor signaling pathway—PIK3CA—head and neck cancer	7.9e-05	0.00148	CbGpPWpGaD
Mitoxantrone—BTK—Fc epsilon receptor (FCERI) signaling—MAPK3—head and neck cancer	7.89e-05	0.00147	CbGpPWpGaD
Mitoxantrone—BTK—DAP12 interactions—MAPK3—head and neck cancer	7.89e-05	0.00147	CbGpPWpGaD
Mitoxantrone—Rash—Docetaxel—head and neck cancer	7.84e-05	0.00084	CcSEcCtD
Mitoxantrone—Dermatitis—Docetaxel—head and neck cancer	7.83e-05	0.00084	CcSEcCtD
Mitoxantrone—CYP1B1—Metapathway biotransformation—CYP1A1—head and neck cancer	7.82e-05	0.00146	CbGpPWpGaD
Mitoxantrone—Headache—Docetaxel—head and neck cancer	7.79e-05	0.000835	CcSEcCtD
Mitoxantrone—TOP2A—Mitotic G1-G1/S phases—CCND1—head and neck cancer	7.72e-05	0.00144	CbGpPWpGaD
Mitoxantrone—CYP1B1—Aryl Hydrocarbon Receptor—HRAS—head and neck cancer	7.71e-05	0.00144	CbGpPWpGaD
Mitoxantrone—BTK—DAP12 interactions—MAPK1—head and neck cancer	7.5e-05	0.0014	CbGpPWpGaD
Mitoxantrone—BTK—Fc epsilon receptor (FCERI) signaling—MAPK1—head and neck cancer	7.5e-05	0.0014	CbGpPWpGaD
Mitoxantrone—BTK—DAP12 interactions—EGFR—head and neck cancer	7.5e-05	0.0014	CbGpPWpGaD
Mitoxantrone—BTK—Fc epsilon receptor (FCERI) signaling—EGFR—head and neck cancer	7.5e-05	0.0014	CbGpPWpGaD
Mitoxantrone—Nausea—Docetaxel—head and neck cancer	7.38e-05	0.000792	CcSEcCtD
Mitoxantrone—ABCG2—HIF-1-alpha transcription factor network—VEGFA—head and neck cancer	7.27e-05	0.00136	CbGpPWpGaD
Mitoxantrone—TOP2A—Retinoblastoma (RB) in Cancer—TP53—head and neck cancer	7.23e-05	0.00135	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism—UROD—head and neck cancer	7.21e-05	0.00135	CbGpPWpGaD
Mitoxantrone—ABCG2—Transmembrane transport of small molecules—ATP7B—head and neck cancer	7.11e-05	0.00133	CbGpPWpGaD
Mitoxantrone—ABCB1—lymphoid tissue—head and neck cancer	7.07e-05	0.00585	CbGeAlD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—RARB—head and neck cancer	7e-05	0.00131	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism—UROD—head and neck cancer	6.97e-05	0.0013	CbGpPWpGaD
Mitoxantrone—BTK—B Cell Activation—EGFR—head and neck cancer	6.94e-05	0.0013	CbGpPWpGaD
Mitoxantrone—BTK—DAP12 signaling—PIK3CA—head and neck cancer	6.92e-05	0.00129	CbGpPWpGaD
Mitoxantrone—CYP3A4—Tryptophan metabolism—CYP1A1—head and neck cancer	6.9e-05	0.00129	CbGpPWpGaD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—BCL2—head and neck cancer	6.82e-05	0.00127	CbGpPWpGaD
Mitoxantrone—CYP2E1—Vitamin A and Carotenoid Metabolism—MAPK1—head and neck cancer	6.62e-05	0.00124	CbGpPWpGaD
Mitoxantrone—BTK—Fc epsilon receptor (FCERI) signaling—PIK3CA—head and neck cancer	6.51e-05	0.00122	CbGpPWpGaD
Mitoxantrone—BTK—DAP12 interactions—PIK3CA—head and neck cancer	6.51e-05	0.00122	CbGpPWpGaD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—PTGS2—head and neck cancer	6.48e-05	0.00121	CbGpPWpGaD
Mitoxantrone—BTK—Regulation of toll-like receptor signaling pathway—AKT1—head and neck cancer	6.45e-05	0.00121	CbGpPWpGaD
Mitoxantrone—ABCB1—thyroid gland—head and neck cancer	6.42e-05	0.00532	CbGeAlD
Mitoxantrone—BTK—DAP12 signaling—HRAS—head and neck cancer	6.4e-05	0.0012	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—RAD51—head and neck cancer	6.37e-05	0.00119	CbGpPWpGaD
Mitoxantrone—ABCG2—Metabolism—UROD—head and neck cancer	6.34e-05	0.00119	CbGpPWpGaD
Mitoxantrone—BTK—Innate Immune System—BCL2L1—head and neck cancer	6.17e-05	0.00115	CbGpPWpGaD
Mitoxantrone—BTK—B Cell Activation—PIK3CA—head and neck cancer	6.03e-05	0.00113	CbGpPWpGaD
Mitoxantrone—BTK—DAP12 interactions—HRAS—head and neck cancer	6.02e-05	0.00113	CbGpPWpGaD
Mitoxantrone—BTK—Fc epsilon receptor (FCERI) signaling—HRAS—head and neck cancer	6.02e-05	0.00113	CbGpPWpGaD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—CCND1—head and neck cancer	5.85e-05	0.00109	CbGpPWpGaD
Mitoxantrone—ABCB1—head—head and neck cancer	5.7e-05	0.00472	CbGeAlD
Mitoxantrone—BTK—DAP12 signaling—AKT1—head and neck cancer	5.65e-05	0.00106	CbGpPWpGaD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—PTEN—head and neck cancer	5.65e-05	0.00106	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle, Mitotic—TYMS—head and neck cancer	5.63e-05	0.00105	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism of lipids and lipoproteins—YAP1—head and neck cancer	5.59e-05	0.00105	CbGpPWpGaD
Mitoxantrone—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—head and neck cancer	5.58e-05	0.00104	CbGpPWpGaD
Mitoxantrone—BTK—B Cell Activation—HRAS—head and neck cancer	5.58e-05	0.00104	CbGpPWpGaD
Mitoxantrone—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—head and neck cancer	5.51e-05	0.00103	CbGpPWpGaD
Mitoxantrone—CYP2E1—Biological oxidations—GSTM1—head and neck cancer	5.46e-05	0.00102	CbGpPWpGaD
Mitoxantrone—TOP2A—Circadian rythm related genes—PTEN—head and neck cancer	5.42e-05	0.00101	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism of lipids and lipoproteins—YAP1—head and neck cancer	5.41e-05	0.00101	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metapathway biotransformation—GSTM1—head and neck cancer	5.39e-05	0.00101	CbGpPWpGaD
Mitoxantrone—BTK—Fc epsilon receptor (FCERI) signaling—AKT1—head and neck cancer	5.32e-05	0.000995	CbGpPWpGaD
Mitoxantrone—BTK—DAP12 interactions—AKT1—head and neck cancer	5.32e-05	0.000995	CbGpPWpGaD
Mitoxantrone—ABCB1—Allograft Rejection—CASP8—head and neck cancer	5.3e-05	0.000991	CbGpPWpGaD
Mitoxantrone—CYP2E1—Biological oxidations—CYP1A1—head and neck cancer	5.18e-05	0.000968	CbGpPWpGaD
Mitoxantrone—CYP3A4—Biological oxidations—NAT2—head and neck cancer	5.13e-05	0.000959	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metapathway biotransformation—CYP1A1—head and neck cancer	5.11e-05	0.000955	CbGpPWpGaD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—VEGFA—head and neck cancer	5.1e-05	0.000954	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metapathway biotransformation—NAT2—head and neck cancer	5.06e-05	0.000946	CbGpPWpGaD
Mitoxantrone—BTK—Innate Immune System—CASP8—head and neck cancer	5.04e-05	0.000943	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle—TYMS—head and neck cancer	5.03e-05	0.000941	CbGpPWpGaD
Mitoxantrone—BTK—B Cell Activation—AKT1—head and neck cancer	4.92e-05	0.000921	CbGpPWpGaD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—MAPK3—head and neck cancer	4.83e-05	0.000902	CbGpPWpGaD
Mitoxantrone—BTK—Adaptive Immune System—CDH1—head and neck cancer	4.79e-05	0.000895	CbGpPWpGaD
Mitoxantrone—ABCG2—HIF-1-alpha transcription factor network—AKT1—head and neck cancer	4.64e-05	0.000867	CbGpPWpGaD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—MAPK1—head and neck cancer	4.59e-05	0.000858	CbGpPWpGaD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—EGFR—head and neck cancer	4.59e-05	0.000858	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—UROD—head and neck cancer	4.55e-05	0.000852	CbGpPWpGaD
Mitoxantrone—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—head and neck cancer	4.52e-05	0.000846	CbGpPWpGaD
Mitoxantrone—BTK—Innate Immune System—BCL2—head and neck cancer	4.33e-05	0.000809	CbGpPWpGaD
Mitoxantrone—ABCB1—Allograft Rejection—IL2—head and neck cancer	4e-05	0.000749	CbGpPWpGaD
Mitoxantrone—ABCB1—lymph node—head and neck cancer	3.99e-05	0.0033	CbGeAlD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—PIK3CA—head and neck cancer	3.98e-05	0.000745	CbGpPWpGaD
Mitoxantrone—ABCB1—HIF-1-alpha transcription factor network—VEGFA—head and neck cancer	3.93e-05	0.000735	CbGpPWpGaD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—TP53—head and neck cancer	3.85e-05	0.000721	CbGpPWpGaD
Mitoxantrone—ABCB1—Transmembrane transport of small molecules—ATP7B—head and neck cancer	3.85e-05	0.000719	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—TYMS—head and neck cancer	3.83e-05	0.000715	CbGpPWpGaD
Mitoxantrone—TOP2A—Circadian rythm related genes—TP53—head and neck cancer	3.7e-05	0.000692	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—BCL2L1—head and neck cancer	3.59e-05	0.000672	CbGpPWpGaD
Mitoxantrone—BTK—Innate Immune System—PTEN—head and neck cancer	3.59e-05	0.000671	CbGpPWpGaD
Mitoxantrone—BTK—Adaptive Immune System—PTEN—head and neck cancer	3.44e-05	0.000644	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—UROD—head and neck cancer	3.43e-05	0.000641	CbGpPWpGaD
Mitoxantrone—ABCB1—Allograft Rejection—VEGFA—head and neck cancer	3.4e-05	0.000636	CbGpPWpGaD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—AKT1—head and neck cancer	3.25e-05	0.000609	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	3.18e-05	0.000594	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	3.15e-05	0.000588	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	3.07e-05	0.000575	CbGpPWpGaD
Mitoxantrone—BTK—Innate Immune System—MAPK3—head and neck cancer	3.06e-05	0.000573	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	3.04e-05	0.000569	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism—NAT2—head and neck cancer	2.99e-05	0.00056	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—CASP8—head and neck cancer	2.94e-05	0.000549	CbGpPWpGaD
Mitoxantrone—BTK—Innate Immune System—MAPK1—head and neck cancer	2.92e-05	0.000545	CbGpPWpGaD
Mitoxantrone—BTK—Innate Immune System—EGFR—head and neck cancer	2.92e-05	0.000545	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—CDH1—head and neck cancer	2.9e-05	0.000543	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism—NAT2—head and neck cancer	2.9e-05	0.000541	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle, Mitotic—CCND1—head and neck cancer	2.83e-05	0.00053	CbGpPWpGaD
Mitoxantrone—BTK—Adaptive Immune System—EGFR—head and neck cancer	2.8e-05	0.000523	CbGpPWpGaD
Mitoxantrone—ABCG2—Metabolism—NAT2—head and neck cancer	2.63e-05	0.000493	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism—DPYD—head and neck cancer	2.62e-05	0.000491	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—CASP8—head and neck cancer	2.62e-05	0.000489	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism—DPYD—head and neck cancer	2.54e-05	0.000475	CbGpPWpGaD
Mitoxantrone—CYP3A4—Biological oxidations—GSTM1—head and neck cancer	2.53e-05	0.000474	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle—CCND1—head and neck cancer	2.53e-05	0.000474	CbGpPWpGaD
Mitoxantrone—BTK—Innate Immune System—PIK3CA—head and neck cancer	2.53e-05	0.000473	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—BCL2—head and neck cancer	2.52e-05	0.000471	CbGpPWpGaD
Mitoxantrone—ABCB1—HIF-1-alpha transcription factor network—AKT1—head and neck cancer	2.51e-05	0.000469	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metapathway biotransformation—GSTM1—head and neck cancer	2.5e-05	0.000467	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism—YAP1—head and neck cancer	2.49e-05	0.000466	CbGpPWpGaD
Mitoxantrone—BTK—Adaptive Immune System—PIK3CA—head and neck cancer	2.43e-05	0.000454	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism—YAP1—head and neck cancer	2.41e-05	0.00045	CbGpPWpGaD
Mitoxantrone—CYP3A4—Biological oxidations—CYP1A1—head and neck cancer	2.4e-05	0.000449	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metapathway biotransformation—CYP1A1—head and neck cancer	2.37e-05	0.000443	CbGpPWpGaD
Mitoxantrone—BTK—Innate Immune System—HRAS—head and neck cancer	2.34e-05	0.000438	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle, Mitotic—MAPK3—head and neck cancer	2.34e-05	0.000437	CbGpPWpGaD
Mitoxantrone—ABCG2—Metabolism—DPYD—head and neck cancer	2.31e-05	0.000432	CbGpPWpGaD
Mitoxantrone—BTK—Adaptive Immune System—HRAS—head and neck cancer	2.25e-05	0.00042	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—BCL2—head and neck cancer	2.24e-05	0.00042	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle, Mitotic—MAPK1—head and neck cancer	2.22e-05	0.000416	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—IL2—head and neck cancer	2.22e-05	0.000415	CbGpPWpGaD
Mitoxantrone—ABCG2—Metabolism—YAP1—head and neck cancer	2.19e-05	0.00041	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—head and neck cancer	2.13e-05	0.000399	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—UROD—head and neck cancer	2.11e-05	0.000395	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—PTEN—head and neck cancer	2.09e-05	0.000391	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle—MAPK3—head and neck cancer	2.09e-05	0.000391	CbGpPWpGaD
Mitoxantrone—BTK—Innate Immune System—AKT1—head and neck cancer	2.07e-05	0.000386	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle—MAPK1—head and neck cancer	1.99e-05	0.000372	CbGpPWpGaD
Mitoxantrone—BTK—Adaptive Immune System—AKT1—head and neck cancer	1.98e-05	0.000371	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—head and neck cancer	1.93e-05	0.00036	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—NAT2—head and neck cancer	1.89e-05	0.000354	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	1.87e-05	0.00035	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—STAT3—head and neck cancer	1.87e-05	0.000349	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—head and neck cancer	1.86e-05	0.000348	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	1.81e-05	0.000338	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—MAPK3—head and neck cancer	1.78e-05	0.000334	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—MAPK1—head and neck cancer	1.7e-05	0.000318	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—EGFR—head and neck cancer	1.7e-05	0.000317	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—head and neck cancer	1.68e-05	0.000314	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle—TP53—head and neck cancer	1.67e-05	0.000312	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—DPYD—head and neck cancer	1.66e-05	0.00031	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	1.63e-05	0.000305	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK3—head and neck cancer	1.59e-05	0.000297	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	1.58e-05	0.000295	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—YAP1—head and neck cancer	1.57e-05	0.000294	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—head and neck cancer	1.51e-05	0.000283	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—head and neck cancer	1.51e-05	0.000283	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism—TYMS—head and neck cancer	1.5e-05	0.00028	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism—GSTM1—head and neck cancer	1.48e-05	0.000276	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—PIK3CA—head and neck cancer	1.47e-05	0.000276	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism—TYMS—head and neck cancer	1.45e-05	0.00027	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism—GSTM1—head and neck cancer	1.43e-05	0.000267	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—NAT2—head and neck cancer	1.42e-05	0.000266	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism—GPX1—head and neck cancer	1.42e-05	0.000265	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism—CYP1A1—head and neck cancer	1.4e-05	0.000262	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism—GPX1—head and neck cancer	1.37e-05	0.000256	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—HRAS—head and neck cancer	1.36e-05	0.000255	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism—CYP1A1—head and neck cancer	1.36e-05	0.000253	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—NOTCH1—head and neck cancer	1.34e-05	0.000251	CbGpPWpGaD
Mitoxantrone—ABCG2—Metabolism—TYMS—head and neck cancer	1.32e-05	0.000246	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—head and neck cancer	1.31e-05	0.000245	CbGpPWpGaD
Mitoxantrone—ABCG2—Metabolism—GSTM1—head and neck cancer	1.3e-05	0.000243	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—head and neck cancer	1.27e-05	0.000237	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—DPYD—head and neck cancer	1.25e-05	0.000233	CbGpPWpGaD
Mitoxantrone—ABCG2—Metabolism—GPX1—head and neck cancer	1.25e-05	0.000233	CbGpPWpGaD
Mitoxantrone—ABCG2—Metabolism—CYP1A1—head and neck cancer	1.23e-05	0.000231	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—AKT1—head and neck cancer	1.2e-05	0.000225	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—YAP1—head and neck cancer	1.19e-05	0.000222	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	1.15e-05	0.000215	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	1.11e-05	0.000208	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—head and neck cancer	1.07e-05	0.0002	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—PTGS2—head and neck cancer	9.95e-06	0.000186	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—TYMS—head and neck cancer	9.45e-06	0.000177	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—GSTM1—head and neck cancer	9.34e-06	0.000175	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—GPX1—head and neck cancer	8.94e-06	0.000167	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—CYP1A1—head and neck cancer	8.85e-06	0.000166	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—NAT2—head and neck cancer	8.77e-06	0.000164	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—PTEN—head and neck cancer	8.68e-06	0.000162	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism—PTGS2—head and neck cancer	8.34e-06	0.000156	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism—PTGS2—head and neck cancer	8.06e-06	0.000151	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—STAT3—head and neck cancer	7.76e-06	0.000145	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—DPYD—head and neck cancer	7.69e-06	0.000144	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—MAPK3—head and neck cancer	7.42e-06	0.000139	CbGpPWpGaD
Mitoxantrone—ABCG2—Metabolism—PTGS2—head and neck cancer	7.33e-06	0.000137	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—YAP1—head and neck cancer	7.3e-06	0.000137	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism—PTEN—head and neck cancer	7.27e-06	0.000136	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—TYMS—head and neck cancer	7.12e-06	0.000133	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—MAPK1—head and neck cancer	7.06e-06	0.000132	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—EGFR—head and neck cancer	7.06e-06	0.000132	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—GSTM1—head and neck cancer	7.03e-06	0.000132	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism—PTEN—head and neck cancer	7.03e-06	0.000131	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—GPX1—head and neck cancer	6.74e-06	0.000126	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—CYP1A1—head and neck cancer	6.67e-06	0.000125	CbGpPWpGaD
Mitoxantrone—ABCG2—Metabolism—PTEN—head and neck cancer	6.4e-06	0.00012	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—PIK3CA—head and neck cancer	6.12e-06	0.000114	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—HRAS—head and neck cancer	5.67e-06	0.000106	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—PTGS2—head and neck cancer	5.27e-06	9.85e-05	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism—PIK3CA—head and neck cancer	5.13e-06	9.59e-05	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—AKT1—head and neck cancer	5e-06	9.35e-05	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism—PIK3CA—head and neck cancer	4.96e-06	9.27e-05	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—PTEN—head and neck cancer	4.59e-06	8.59e-05	CbGpPWpGaD
Mitoxantrone—ABCG2—Metabolism—PIK3CA—head and neck cancer	4.51e-06	8.44e-05	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—TYMS—head and neck cancer	4.38e-06	8.2e-05	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—GSTM1—head and neck cancer	4.33e-06	8.1e-05	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism—AKT1—head and neck cancer	4.19e-06	7.83e-05	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—GPX1—head and neck cancer	4.15e-06	7.76e-05	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—CYP1A1—head and neck cancer	4.11e-06	7.68e-05	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism—AKT1—head and neck cancer	4.05e-06	7.58e-05	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—PTGS2—head and neck cancer	3.97e-06	7.41e-05	CbGpPWpGaD
Mitoxantrone—ABCG2—Metabolism—AKT1—head and neck cancer	3.69e-06	6.89e-05	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—PTEN—head and neck cancer	3.46e-06	6.47e-05	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—PIK3CA—head and neck cancer	3.24e-06	6.06e-05	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—AKT1—head and neck cancer	2.65e-06	4.95e-05	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—PTGS2—head and neck cancer	2.44e-06	4.57e-05	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—PIK3CA—head and neck cancer	2.44e-06	4.56e-05	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—PTEN—head and neck cancer	2.13e-06	3.98e-05	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—AKT1—head and neck cancer	1.99e-06	3.73e-05	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—PIK3CA—head and neck cancer	1.5e-06	2.81e-05	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—AKT1—head and neck cancer	1.23e-06	2.3e-05	CbGpPWpGaD
